Synthesis, Structural Characterization, and Preclinical Efficacy of a Novel Paclitaxel-Loaded Alginate Nanoparticle for Breast Cancer Treatment

被引:36
作者
Markeb, Ahmed A. [1 ]
El-Maali, Nagwa A. [1 ]
Sayed, Douaa M. [2 ]
Osama, Amany [3 ]
Abdel-Malek, Mohamed A. Y. [4 ,5 ]
Zaki, Amen H. [6 ]
Elwanis, Mostafa E. A. [7 ]
Driscoll, James J. [5 ,8 ]
机构
[1] Assiut Univ, Dept Chem, Fac Sci, Assiut 71516, Egypt
[2] Assiut Univ, South Egypt Canc Inst, Dept Oncol Clin Pathol, Assiut 71516, Egypt
[3] Assiut Univ, Dept Med Biochem, Fac Med, Assiut 71515, Egypt
[4] Assiut Univ, Dept Clin Pathol, Fac Med, Assiut 71515, Egypt
[5] Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Cincinnati, OH 45220 USA
[6] Assiut Univ, South Egypt Canc Inst, Dept Med Oncol, Assiut, Egypt
[7] Assiut Univ, South Egypt Canc Inst, Dept Radiotherapy, Assiut, Egypt
[8] Univ Cincinnati, Inst Canc, Cincinnati, OH 45220 USA
关键词
D O I
10.1155/2016/7549372
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The antitumor activity of a novel alginate (ALG) polymer-based particle that contained paclitaxel (PTX) was evaluated using human primary breast cancer cells. Materials and Methods. PTX was combined with ALG in a nanoparticle as a drug delivery system designed to improve breast cancer tumor cell killing. PTX-ALG nanoparticles were first synthesized by nanoemulsification polymer cross-linking methods that improved the aqueous solubility. Structural and biophysical properties of the PTX-ALG nanoparticles were then determined by transmission electron microscopy (TEM) and high performance liquid chromatography (HPLC) fluorescence. The effect on cell cycle progression and apoptosis was determined using flow cytometry. Results. PTX-ALG nanoparticles were prepared and characterized by ultraviolet (UV)/visible (VIS), HPLC fluorescence, and TEM. PTX-ALG nanoparticles demonstrated increased hydrophobicity and solubility over PTX alone. Synthetically engineered PTX-ALG nanoparticles promoted cell-cycle arrest, reduced viability, and induced apoptosis in human primary patient breast cancer cells superior to those of PTX alone. Conclusion. Taken together, our results demonstrate that PTX-ALG nanoparticles represent an innovative, nanoscale delivery system for the administration of anticancer agents that may avoid the adverse toxicities with enhanced antitumor effects to improve the treatment of breast cancer patients.
引用
收藏
页数:8
相关论文
共 25 条
[1]   Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer [J].
Di Leo, Angelo ;
Gomez, Henry L. ;
Aziz, Zeba ;
Zvirbule, Zanete ;
Bines, Jose ;
Arbushites, Michael C. ;
Guerrera, Stephanie F. ;
Koehler, Maria ;
Oliva, Cristina ;
Stein, Steven H. ;
Williams, Lisa S. ;
Dering, Judy ;
Finn, Richard S. ;
Press, Michael F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) :5544-5552
[2]   The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[3]   Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers [J].
Feng, SS ;
Huang, GF .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (01) :53-69
[4]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171
[5]   Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity [J].
Fonseca, C ;
Simoes, S ;
Gaspar, R .
JOURNAL OF CONTROLLED RELEASE, 2002, 83 (02) :273-286
[6]   Polymer therapeutics: Concepts and applications [J].
Haag, R ;
Kratz, F .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2006, 45 (08) :1198-1215
[7]   NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel [J].
Hamaguchi, T ;
Matsumura, Y ;
Suzuki, M ;
Shimizu, K ;
Goda, R ;
Nakamura, I ;
Nakatomi, I ;
Yokoyama, M ;
Kataoka, K ;
Kakizoe, T .
BRITISH JOURNAL OF CANCER, 2005, 92 (07) :1240-1246
[8]   BREAST CANCER: Challenges, controversies, breakthroughs [J].
Hutchinson, Lisa .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (12) :669-670
[9]  
Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]
[10]  
Kato K, 2006, J CLIN ONCOL, V24, p83S